The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
10.3349/ymj.2015.56.6.1638
- Author:
Juhan LEE
1
;
Beom Seok KIM
;
Yongjung PARK
;
Jae Geun LEE
;
Beom Jin LIM
;
Hyeon Joo JEONG
;
Yu Seun KIM
;
Kyu Ha HUH
Author Information
1. The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea. khhuh@yuhs.ac
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Angiotensin II type 1 receptor antibodies;
antibody-mediated rejection;
bortezomib;
HLA antibodies;
kidney transplantation
- MeSH:
Adolescent;
Adult;
Antibodies, Monoclonal/therapeutic use;
Antineoplastic Agents/*therapeutic use;
Boronic Acids/therapeutic use;
Bortezomib/*therapeutic use;
Female;
Graft Rejection/*drug therapy/*prevention & control;
Humans;
Immunoglobulins, Intravenous/therapeutic use;
Immunologic Factors/therapeutic use;
Isoantibodies;
Kidney Failure, Chronic/*surgery;
*Kidney Transplantation;
Male;
Middle Aged;
Plasmapheresis;
Pyrazines/administration & dosage;
Transplantation, Homologous
- From:Yonsei Medical Journal
2015;56(6):1638-1642
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when bortezomib was used to treat refractory AMR. MATERIALS AND METHODS: Eleven refractory AMR episodes treated with bortezomib were included in this study. The patients received one or two cycles of bortezomib (1.3 mg/m2) on days 1, 4, 8, and 11. RESULTS: Bortezomib effectively reduced antibodies against various targets, including human leukocyte antigen (HLA) class I and II, ABO blood group antigen, and angiotensin II type 1 receptor. Antibodies were depleted or reduced significantly in eight AMR episodes. Overall, there was a significant improvement in the mean estimated glomerular filtration rate (eGFR) at 3 months after therapy (36.91+/-22.15 mL/min/1.73 m2) versus eGFR at time of AMR diagnosis (17.00+/-9.25 mL/min/1.73 m2; p=0.007). All six early-onset AMR episodes (within 6 months post-transplantation) showed full recovery of allograft function. Additionally, three of the five late-onset AMR episodes (>6 months post-transplantation) showed improved allograft function. CONCLUSION: Anti-humoral treatment based on bortezomib might be an effective strategy against refractory AMR caused by various types of antibodies. Notably, this treatment could be more effective in early-onset AMR than in late-onset AMR.
